Skip to main content

Guanabenz Disease Interactions

There are 5 disease interactions with guanabenz.

Moderate

Alpha-2 agonists (central) (applies to guanabenz) bradyarrhythmia

Moderate Potential Hazard, High plausibility. Applicable conditions: Heart Block, Sinus Node Dysfunction

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system. Heart rate is decreased, which may lead to or exacerbate sinus bradycardia and atrioventricular block. Therapy with central alpha-2 adrenoreceptor agonists should be administered cautiously in patients with conduction disturbances such as sinus node dysfunction or AV nodal disease.

References

  1. Byrd BF, Collins HW, Primm RK (1988) "Risk factors for severe bradycardia during oral clonidine therapy for hypertension." Arch Intern Med, 148, p. 729-33
  2. van Zwieten PA, Thoolen MJ, Timmermans PB (1984) "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine." Hypertension, 6, p. 28-33
  3. Schwartz E, Friedman E, Mouallem M, Farfel Z (1988) "Sinus arrest associated with clonidine therapy." Clin Cardiol, 11, p. 53-4
  4. (2001) "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories
  6. Golusinski LL, Blount BW (1995) "Clonidine-induced bradycardia." J Fam Pract, 41, p. 399-401
  7. (2001) "Product Information. Catapres (clonidine)." Boehringer-Ingelheim
View all 7 references
Moderate

Alpha-2 agonists (central) (applies to guanabenz) depression

Moderate Potential Hazard, Moderate plausibility.

Central alpha-2 adrenoreceptor agonists may occasionally cause mental depression and should be used cautiously in patients with a history of depression.

References

  1. Kostis JB, Rosen RC, Holzer BC, et al. (1990) "CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males." Psychopharmacology (Berl), 102, p. 163-70
  2. Prasad A, Shotliff K (1993) "Depression and chronic clonidine therapy." Postgrad Med J, 69, p. 327-8
  3. (2001) "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Catapres (clonidine)." Boehringer-Ingelheim
View all 5 references
Moderate

Alpha-2 agonists (central) (applies to guanabenz) hypotension

Moderate Potential Hazard, High plausibility. Applicable conditions: Cerebrovascular Insufficiency, Ischemic Heart Disease, Peripheral Arterial Disease

Central alpha-2 adrenoreceptor agonists reduce sympathetic outflow from the central nervous system, resulting in decreases in heart rate, peripheral and renovascular resistance, and blood pressure. Therapy with these agents should be administered cautiously in patients with hypotension or conditions that may be exacerbated by decreased blood pressure and perfusion, such as coronary insufficiency, peripheral vascular disease (e.g., Raynaud's syndrome), cerebrovascular disease, or recent myocardial infarction.

References

  1. Anavekar SN, Jarrott B, Toscano M, Louis WJ (1982) "Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects." Eur J Clin Pharmacol, 23, p. 1-5
  2. Fruncillo RJ, Gibbons WJ, Vlasses PH, Ferguson RK (1985) "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry, 142, p. 274
  3. Bosanac P, Dubb J, Walker B, et al. (1976) "Renal effects of guanabenz: a new antihypertensive." J Clin Pharmacol, Nov-Dec, p. 631-6
  4. Bauer JH (1983) "Effects of guanabenz therapy on renal function and body fluid composition." Arch Intern Med, 143, p. 1163-7
  5. Dziedzic SW, Elijovich F, Felton K, et al. (1983) "Effect of guanabenz on blood pressure responses to posture and exercise." Clin Pharmacol Ther, 33, p. 151-5
  6. Mosley C, O'Connor DT, Taylor A, et al. (1984) "Comparative effects of antihypertensive therapy with guanabenz and propranolol on renal vascular resistance and left ventricular mass." J Cardiovasc Pharmacol, 6, s757-61
  7. Greene CS, Gretler DD, Cervenka K, et al. (1990) "Cerebral blood flow during the acute therapy of severe hypertension with oral clonidine." Am J Emerg Med, 8, p. 293-6
  8. Given BD, Taylor T, Lilly LS, Dzau VJ (1983) "Symptomatic hypotension following the clonidine suppression test for pheochromocytoma." Arch Intern Med, 143, p. 2195-6
  9. van Zwieten PA, Thoolen MJ, Timmermans PB (1984) "The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine." Hypertension, 6, p. 28-33
  10. (2001) "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories
  11. (2001) "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories
  12. (2001) "Product Information. Catapres (clonidine)." Boehringer-Ingelheim
View all 12 references
Moderate

Guanabenz (applies to guanabenz) liver disease

Moderate Potential Hazard, High plausibility.

Guanabenz is primarily metabolized by the liver. Pharmacokinetic data indicate that the plasma clearance of guanabenz is significantly reduced and its elimination half-life significantly prolonged in patients with liver disease. Therapy with guanabenz should be administered cautiously in patients with impaired hepatic function. Careful monitoring of blood pressure during dosage titration is recommended.

References

  1. Lasseter KC, Shapse D, Pascucci VL, Chiang ST (1984) "Pharmacokinetics of guanabenz in patients with impaired liver function." J Cardiovasc Pharmacol, 6, s766-70
  2. (2001) "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories
Moderate

Guanabenz (applies to guanabenz) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

The disposition of orally administered guanabenz is altered modestly in renal impairment. The manufacturer states that the plasma clearance of guanabenz is reduced and its half-life prolonged in patients with impaired renal function, and more so in those on hemodialysis. The clinical significance of these findings is unknown. Careful monitoring of blood pressure during dosage titration is recommended.

References

  1. Dubrow A, Mittman N, DeCola P, et al. (1985) "Safety and efficacy of guanabenz in hypertensive patients with moderate renal insufficiency." J Clin Hypertens, 1, p. 322-5
  2. (2001) "Product Information. Wytensin (guanabenz)." Wyeth-Ayerst Laboratories

Guanabenz drug interactions

There are 178 drug interactions with guanabenz.

Guanabenz alcohol/food interactions

There is 1 alcohol/food interaction with guanabenz.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer